Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Jason_Park
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
drug discovery
small molecule therapeutics |
| gptkbp:foundedYear |
2022
|
| gptkbp:founder |
gptkb:Flagship_Pioneering
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:mission |
to accelerate the discovery of new medicines
|
| gptkbp:parentCompany |
gptkb:Flagship_Pioneering
|
| gptkbp:platform |
chemistry-based drug discovery
|
| gptkbp:website |
https://www.empresstx.com/
|
| gptkbp:bfsParent |
gptkb:Mark_Leschly
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Empress Therapeutics
|